Page 2007 - Williams Hematology ( PDFDrive )

1982 Part XII: Hemostasis and Thrombosis Chapter 115: Vascular Function In Hemostasis 1983

152. Cesarman-Maus G, Rios-Luna NP, Deora AB, et al: Autoantibodies against the fibrino- 186. Konstantinides S, Schafer K, Loskutoff DJ: Do PAI-1 and vitronectin promote or inhbiit
lytic receptor, annexin 2, in antiphospholipid syndrome. Blood 107:4375–4382, 2006. neointima formation? Arterioscler Thromb Vasc Biol 22:1943–1945, 2002.
153. Cesarman-Maus G, Cantu-Brito C, Barinagarrementeria F, et al: Autoantibodies against 187. Eitzman DT, Westrick RJ, Nabel EG, Ginsburg D: Plasminogen activator inhibitor-1
the fibrinolytic receptor, annexin A2, in cerebral venous thrombosis. Stroke 42:501– and vitronectin promote vascular thrombosis in mice. Blood 95:577–580, 2000.
503, 2011. 188. Konstantinides S, Schafer K, Thinnes T, Loskutoff DJ: Plasminogen activator inhibi-
154. Sebastiani P, Ramoni MF, Nolan V, et al: Genetic dissection and prognostic modeling of tor-1 and its cofacor vitronectin stabilize arterial thrombi following vascular injury in
overt stroke in sickle cell anemia. Nat Genet 37:435–440, 2005. mice. Circulation 103:576–583, 2001.
155. Flanagan JM, Frohlich DM, Howard TA, et al: Genetic predictors for stroke in children 189. Schafer K, Konstantinides S, Riedel C, et al: Different mechanisms of increased luminal
with sickle cell anemia. Blood 117:6681–6684, 2011. stenosis after arterial injury in mice deficient for urokinase- or tissue-type plasminogen
156. Baldwin CT, Nolan VG, Wyszynski DF, et al: Association of klotho, bone morphoge- activator. Circulation 106:1847–1852, 2002.
netic protein 6, and annexin A2 polymorphisms with sickle cell disease. Blood 106: 190. Schafer K, Muller K, Hecker A, et al: Enhanced thrombosis in atherosclerosis-prone
372–375, 2005. mice is associated with increased arterial expression of plasmingen activator. Arterio-
157. Surette AP, Madureira PA, Phipps KD, et al: Regulation of fibrinolysis by S100A10 in scler Thromb Vasc Biol 23:2097–2103, 2003.
vivo. Blood 118:3172–3181, 2011. 191. Zhu Y, Farrehi PM, Fay WP: Plasminogen activator inhibitor type 1 enhances neoin-
158. Omar MN, Mann KG: Inactivation of factor Va by plasmin. J Biol Chem 262:9750–9755, tima formation after oxidative vascular injury in atherosclerosis-prone mice. Circula-
1987. tion 103:3105–3110, 2001.
159. Esmon CT: The regulation of natural anticoagulant pathways. Science 235:1348–1352, 192. Ploplis VA, Cornelissen I, Sandoval-Cooper MJ, et al: Remodeling of the vessel wall
1987. after copper-induced injury is highly attenuated in mice with a total deficiency of plas-
160. McKee PA, Anderson JC, Switzer ME: Molecular structural studies of human factor minogen activator inhibitor-1. Am J Pathol 158:107–117, 2001.
VIII. Ann N Y Acad Sci 240:8–33, 1975. 193. Peng L, Bhatia N, Parker AC, et al: Endogenous vitronectin and plasminogen activa-
161. Stricker RB, Wong D, Shiu DT, et al: Activation of plasminogen by tissue plasminogen tor inhibitor-1 promote neointima formation in murine carotid arteries. Arterioscler
activator on normal and thrombasthenic platelets: Effects on surface proteins and plate- Thromb Vasc Biol 22:934–939, 2002.
let aggregation. Blood 68:275–280, 1986. 194. DeYoung MB, Tom C, Dichek DA: Plasminogen activator inhibitor type 1 increases neoin-
162. Adelman B, Michelson AD, Greenberg J, Handin RI: Proteolysis of platelet glycoprotein tima formation in balloon-injured rat carotid arteries. Circulation 104:1972–1981, 2001.
by plasmin is facilitated by plasmin lysine-binding regions. Blood 68:1280–1284, 1986. 195. Scanu AM, Fless GM: Lipoprotein(a) heterogeneity and biologic relevance. J Clin Invest
163. Gimple LW, Gold HK, Leinbach RC, et al: Correlation between template bleeding times 85:1709–1715, 1990.
and spontaneous bleeding during treatment of acute myocardial infarction with recom- 196. Utermann G: The mysteries of lipoprotein(a). Science 246:904–910, 1989.
binant issue type plasminogen activator. Blood 80:581–588, 1989. 197. Loscalzo J: Lipoprotein(a), a unique risk factor for atherothrombotic disease. Arterio-
164. Coller BS: Platelets and thrombolytic therapy. N Engl J Med 322:33–42, 1990. sclerosis 10:672–679, 1990.
165. Fay WP, Garg N, Sunkar M: Vascular function of the plasminogen activation system. 198. Hajjar KA, Nachman RL: The role of lipoprotein(a) in atherogenesis and thrombosis.
Arterioscler Thromb Vasc Biol 27:1231–1237, 2007. Annu Rev Med 47:423–442, 1996.
166. Libby P, Aikawa M, Jain MK: Vascular endothelium and atherosclerosis. Handb Exp 199. McLean JW, Tomlinson JE, Kuang WJ, et al: CDNA sequence of human apolipopro-
Pharmacol 176 Part 2:285–306, 2006. tein(a) is homologous to plasminogen. Nature 330:132–137, 1987.
167. Ploplis VA, Carmeliet P, Vazirzadeh S, et al: Effects of disruption of the plasminogen 200. Weitkamp LR, Guttormsen SA, Schultz JS: Linkage between the loci for the Lp(a) lipo-
gene on thrombosis, growth, and health in mice. Circulation 92:2585–2593, 1995. protein (Lp) and plasminogen (PLG). Hum Genet 79:80–82, 1988.
168. Bugge TH, Flick MJ, Daugherty CC, Degen JL: Plasminogen deficiency causes severe 201. Neven L, Khalil A, Pfaffinger D, et al: Rhesus monkey model of familial hypercholes-
thrombosis but is compatible with development and reproduction. Genes Dev 9:794– terolemia: Relation between plasma Lp(a) levels, apo(a) isoforms and LDL-receptor
807, 1995. function. J Lipid Res 31:633–643, 1990.
169. Romer J, Bugge TH, Pyke C, et al: Impaired wound healing in mice with a disrupted 202. Pfaffinger D, Schuelke J, Kim C, et al: Relationship between apo(a) isoforms and Lp(a)
plasminogen gene. Nat Med 2:287–292, 1996. density in subjects with different apo(a) phenotype: A study before and after a fatty
170. Bugge TH, Kombrinck KW, Flick MJ, et al: Loss of fibrinogen rescues mice from the meal. J Lipid Res 32:679–683, 1991.
pleiotropic effects of plasminogen deficiency. Cell 87:709–719, 1996. 203. Utermann G, Menzel HJ, Kraft HG, Duba HC, Kemmler HG, Seitz C: Lp(a) glycopro-
171. Xiao Q, Danton MJS, Witte DP, et al: Plasminogen deficiency accelerates vessel wall dis- tein phenotypes. J Clin Invest 80:458–465, 1987.
ease in mice predisposed to atherosclerosis. Proc Natl Acad Sci U S A 94:10335–10340, 204. Maeda S, Abe A, Seishima M, et al: Transient changes of serum lipoprotein(a) as an
1997. acute phase protein. Atherosclerosis 78:145–150, 1989.
172. Carmeliet P, Moons L, Lijnen R, et al: Urokinase-generated plasmin activates matrix 205. Wright LC, Sullivan DR, Muller M, et al: Elevated apolipoprotein(a) levels in cancer
metalloproteinases during aneurysm formation. Nat Genet 17:439–444, 1997. patients. Int J Cancer 43:241–244, 1989.
173. Eitzman DT, Westrick RJ, Xu Z, et al: Plasminogen activator inhibitor-1 deficiency 206. Gavish D, Azrolan N, Breslow JL: Fish oil reduces plasma Lp(a) levels and affects
protects against atherosclerosis progression in the mouse carotid artery. Blood 96: post-prandial association of apo(a) with triglyceride rich lipoproteins. J Clin Invest
4212–4215, 2000. 84:2021–2027, 1989.
174. Sjoland H, Eitzman DT, Gordon D, et al: Atherosclerosis progression in LDL recep- 207. Koschinsky ML, Beisiegel U, Henne-Bruns D, et al: Apolipoprotein(a) size hetero-
tor-deficient and apolipoprotein E-deficient mice is independent of genetic alterations geneity is related to variable number of repeat sequences in its mRNA. Biochemistry
in plasminogen activator inhibitor-1. Arterioscler Thromb Vasc Biol 20:846–852, 1999. 29:640–644, 1990.
175. Luttun A, Lupu F, Storkebaum E, et al: Lack of plasminogen activator inhibitor-1 pro- 208. Lerch PG, Rickli EE, Lergier W, Gillessen D: Localization of individual lysine-binding
motes growth and abnormal remodeling of advanced atherosclerotic plaque in apolipo- regions in human plasminogen and investiations on their complex-forming properties.
protein E-deficient mice. Arterioscler Thromb Vasc Biol 22:499–505, 2002. Eur J Biochem 107:7–13, 1980.
176. Plow EF, Ploplis VA, Busuttil S, et al: A role of plasminogen in atherosclerosis and rest- 209. Armstrong VW, Harrach B, Robenek H, et al: Heterogeneity of human lipoprotein
enosis models in mice. Thromb Haemost 82 Suppl:4–7, 1999. Lp(a): Cytochemical and biochemical studies on the interaction of two Lp(a) species
177. Ploplis VA, French EL, Carmeliet P, et al: Plasminogen deficiency differentially affects with the LDL receptor. J Lipid Res 31:429–441, 1990.
recruitment of inflammatory cell populations in mice. Blood 91:2005–2009, 1998. 210. Wolf K, Rith M, Niendorf A, et al: Thrombosis: Cellular elements of the vasculature.
178. Moons L, Wi C, Ploplis V, et al: Reduced transplant arteriosclerosis in plasminogen-de- Circulation 80:522, 1989.
ficient mice. J Clin Invest 102:1788–1797, 1998. 211. Grainger DJ, Kemp PR, Liu AC, et al: Activation of transforming growth factor-beta is
179. Heymans S, Luttun A, Nuyens D, et al: Inhibition of plasminogen activators or matrix inhibited in transgenic apolipoprotein(a) mice. Nature 370:460–462, 1994.
metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and 212. Palabrica TM, Liu AC, Aronovitz MJ, et al: Antifibrinolytic activity of apolipoprotein(a)
causes cardiac failure. Nat Med 5:1135–1142, 1999. in vivo: Human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen
180. Lijnen HR, Van Hoef B, Lupu F, et al: Function of the plasminogen/plasmin and matrix activator-mediated thrombolysis. Nat Med 1:256–259, 1995.
metalloproteinase systems after vascular injury in mice with targeted inactivation of 213. Petros AM, Ramesh V, Llinas M: NMR studies of aliphatic ligand binding to human
fibrinolytic system genes. Arterioscler Thromb Vasc Biol 18:1035–1045, 1998. plasminogen kringle 4. Biochemistry 28:1368–1376, 1989.
181. Carmeliet P, Moons L, Ploplis VA, et al: Impaired arterial neointima formation in mice 214. Hajjar KA: The endothelial cell tissue plasminogen activator receptor: Specific interac-
with disruption of the plasminogen gene. J Clin Invest 99:200–208, 1997. tion with plasminogen. J Biol Chem 266:21962–21970, 1991.
182. Carmeliet P, Moons L, Herbert JM, et al: Urokinase but not tissue plasminogen activa- 215. Hajjar KA, Gavish D, Breslow J, Nachman RL: Lipoprotein(a) modulation of endothe-
tor mediates arterial neointima formation in mice. Circ Res 81:829–839, 1997. lial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 339:303–305,
183. Carmeliet P, Moons L, Dewerchin M, et al: Receptor-independent role of urokinase- 1989.
type plasminogen activator in pericellular plasmin and matrix metalloproteinase prote- 216. Gonzales-Gronow M, Edelberg JM, Pizzo SV: Further characterization of the cellular
olysis during vascular wound healing in mice. J Cell Biol 140:233–245, 1998. plasminogen binding site: Evidence that plasminogen 2 and lipoprotein a compete for
184. Carmeliet P, Moons L, Lijnen R, et al: Inhibitory role of plasminogen activator inhibitor-1 the same site. Biochemistry 28:2374–2377, 1989.
in arterial wound healing amd neointima formation. Circulation 96:3180–3191, 1997. 217. Miles LA, Fless GM, Levin EG, et al: A potential basis for the thrombotic risks associ-
185. de Waard V, Armitage RJ, Carmeliet P, et al: Plasminogen activator inhibitor-1 and ated with lipoprotein(a). Nature 339:301–303, 1989.
vitronectin protect against stenosis in a murine carotid ligation model. Arterioscler 218. Edelberg JM, Gonzalez-Gronow M, Pizzo SV: Lipoprotein(a) inhibition of plasmino-
Thromb Vasc Biol 22:1978–1983, 2002. gen activation by tissue-type plasminogen activator. Thromb Res 57:155–162, 1990.

Kaushansky_chapter 115_p1967-1984.indd 1982 9/18/15 10:09 AM